Aligos Therapeutics (ALGS) Competitors

$6.70 +0.03 (+0.45%)

As of 02:39 PM Eastern

ALGS vs. IMUX, HURA, IMDX, GALT, and CRDL

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include Immunic (IMUX), TuHURA Biosciences (HURA), Oncocyte (IMDX), Galectin Therapeutics (GALT), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does Aligos Therapeutics compare to Immunic?

Immunic (NASDAQ:IMUX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Aligos Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Aligos Therapeutics	$2.19M	18.94	-$24.19M	-$8.69	N/A

Immunic presently has a consensus price target of $50.86, indicating a potential upside of 302.77%. Aligos Therapeutics has a consensus price target of $41.50, indicating a potential upside of 519.40%. Given Aligos Therapeutics' higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Aligos Therapeutics had 12 more articles in the media than Immunic. MarketBeat recorded 20 mentions for Aligos Therapeutics and 8 mentions for Immunic. Aligos Therapeutics' average media sentiment score of 0.85 beat Immunic's score of 0.26 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Immunic has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-1,197.81%	-264.95%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

51.8% of Immunic shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 14.0% of Immunic shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats Immunic on 10 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Aligos Therapeutics has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A
Aligos Therapeutics	$2.19M	18.94	-$24.19M	-$8.69	N/A

TuHURA Biosciences presently has a consensus price target of $9.00, indicating a potential upside of 252.25%. Aligos Therapeutics has a consensus price target of $41.50, indicating a potential upside of 519.40%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Aligos Therapeutics had 15 more articles in the media than TuHURA Biosciences. MarketBeat recorded 20 mentions for Aligos Therapeutics and 5 mentions for TuHURA Biosciences. Aligos Therapeutics' average media sentiment score of 0.85 beat TuHURA Biosciences' score of 0.65 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-182.40%	-117.49%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats TuHURA Biosciences on 13 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Oncocyte has a net margin of -1,238.52% compared to Aligos Therapeutics' net margin of -1,919.68%. Oncocyte's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-1,238.52%	N/A	-79.78%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aligos Therapeutics has lower revenue, but higher earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	50.51	-$50.22M	-$1.62	N/A
Aligos Therapeutics	$2.19M	18.94	-$24.19M	-$8.69	N/A

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 2.1% of Oncocyte shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oncocyte presently has a consensus target price of $12.00, indicating a potential upside of 89.42%. Aligos Therapeutics has a consensus target price of $41.50, indicating a potential upside of 519.40%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Aligos Therapeutics had 16 more articles in the media than Oncocyte. MarketBeat recorded 20 mentions for Aligos Therapeutics and 4 mentions for Oncocyte. Aligos Therapeutics' average media sentiment score of 0.85 beat Oncocyte's score of 0.74 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncocyte has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

Summary

Aligos Therapeutics beats Oncocyte on 11 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Galectin Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Galectin Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-214.23%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aligos Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A
Aligos Therapeutics	$2.19M	18.94	-$24.19M	-$8.69	N/A

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 360.25%. Aligos Therapeutics has a consensus target price of $41.50, indicating a potential upside of 519.40%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Aligos Therapeutics had 17 more articles in the media than Galectin Therapeutics. MarketBeat recorded 20 mentions for Aligos Therapeutics and 3 mentions for Galectin Therapeutics. Aligos Therapeutics' average media sentiment score of 0.85 beat Galectin Therapeutics' score of 0.63 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

Summary

Aligos Therapeutics beats Galectin Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Aligos Therapeutics had 10 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 20 mentions for Aligos Therapeutics and 10 mentions for Cardiol Therapeutics. Aligos Therapeutics' average media sentiment score of 0.85 beat Cardiol Therapeutics' score of -0.02 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aligos Therapeutics currently has a consensus target price of $41.50, indicating a potential upside of 519.40%. Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 531.97%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aligos Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	18.94	-$24.19M	-$8.69	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Aligos Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

Aligos Therapeutics beats Cardiol Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.47M	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-0.77	18.81	20.91	25.60
Price / Sales	18.94	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.30	6.78	9.87	6.72
Net Income	-$24.19M	$24.11M	$3.55B	$333.73M
7 Day Performance	11.11%	0.22%	-0.24%	0.38%
1 Month Performance	-23.34%	1.08%	1.44%	4.02%
1 Year Performance	20.50%	78.09%	41.01%	36.37%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	3.302 of 5 stars	$6.70 +0.4%	$41.50 +519.4%	+12.3%	$41.47M	$2.19M	N/A	90	Trending News Earnings Report Short Interest Increase Analyst Revision
IMUX Immunic	3.6776 of 5 stars	$11.28 +6.2%	$52.43 +364.8%	+30.8%	$153.66M	N/A	N/A	70	Earnings Report Upcoming Earnings Analyst Forecast Short Interest Decrease
HURA TuHURA Biosciences	2.7078 of 5 stars	$2.32 +8.4%	$9.00 +287.9%	-38.8%	$147.50M	N/A	N/A	N/A	Upcoming Earnings
IMDX Oncocyte	3.1333 of 5 stars	$4.58 -12.4%	$12.00 +162.0%	N/A	$147.34M	$4.05M	N/A	120	News Coverage Earnings Report High Trading Volume
GALT Galectin Therapeutics	1.7932 of 5 stars	$2.23 -2.6%	$11.00 +393.3%	+68.9%	$146.80M	N/A	N/A	9	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. IMUX, HURA, IMDX, GALT, and CRDL

How does Aligos Therapeutics compare to Immunic?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Summary

How does Aligos Therapeutics compare to Oncocyte?

Summary

How does Aligos Therapeutics compare to Galectin Therapeutics?

Summary

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. IMUX, HURA, IMDX, GALT, and CRDL

How does Aligos Therapeutics compare to Immunic?

Which has stronger earnings & valuation, IMUX or ALGS?

Do analysts prefer IMUX or ALGS?

Does the media favor IMUX or ALGS?

Which has more volatility and risk, IMUX or ALGS?

Is IMUX or ALGS more profitable?

Do institutionals & insiders have more ownership in IMUX or ALGS?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Which has stronger earnings & valuation, HURA or ALGS?

Do analysts prefer HURA or ALGS?

Does the media favor HURA or ALGS?

Which has more volatility and risk, HURA or ALGS?

Is HURA or ALGS more profitable?

Do institutionals & insiders have more ownership in HURA or ALGS?

Summary

How does Aligos Therapeutics compare to Oncocyte?

Is IMDX or ALGS more profitable?

Which has higher earnings and valuation, IMDX or ALGS?

Do insiders and institutionals have more ownership in IMDX or ALGS?

Do analysts rate IMDX or ALGS?

Does the media favor IMDX or ALGS?

Which has more volatility & risk, IMDX or ALGS?

Summary

How does Aligos Therapeutics compare to Galectin Therapeutics?

Is GALT or ALGS more profitable?

Which has higher earnings and valuation, GALT or ALGS?

Do insiders and institutionals have more ownership in GALT or ALGS?

Do analysts rate GALT or ALGS?

Does the media favor GALT or ALGS?

Which has more volatility & risk, GALT or ALGS?

Summary

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Does the media prefer ALGS or CRDL?

Do analysts recommend ALGS or CRDL?

Do institutionals and insiders have more ownership in ALGS or CRDL?

Which has better valuation and earnings, ALGS or CRDL?

Which has more risk and volatility, ALGS or CRDL?

Is ALGS or CRDL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools